You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The Paris-based company plans to use the nucleic acid modification technology to synthesize qPCR probes for use in diagnostics, among other biomolecules.
In addition to discussing Twist's liquid biopsy, NGS-based genotyping and SARS-CoV-2 NGS panel, CEO Emily Leproust touted efforts on DNA data storage.
The firm reported $28.2 million in revenues for the three months ended Dec. 31, 2020, beating consensus Wall Street estimates on the top and bottom lines.
The investment bank said that while Twist's biopharma and DNA-based data storage businesses offer upside, the timelines for generating revenues are unclear.
The funding will help the company further develop its INSPECTR molecular diagnostic platform into a test that can be used in various settings.
Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.
Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.
Science reports that a Dutch research funding agency is combating a ransomware attack.
In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.
In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.
In this session, the fourth in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling identified no clear molecular markers to help guide personalized therapy.